MARKET

AGTC

AGTC

AGTC
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.29
+0.16
+3.12%
Opening 15:50 10/29 EDT
OPEN
5.08
PREV CLOSE
5.13
HIGH
5.35
LOW
4.980
VOLUME
100.79K
TURNOVER
--
52 WEEK HIGH
10.42
52 WEEK LOW
2.290
MARKET CAP
136.79M
P/E (TTM)
-2.4324
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Health Check: How Prudently Does Applied Genetic Technologies (NASDAQ:AGTC) Use Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Simply Wall St. · 2d ago
AGTC to Participate in Cantor Fitzgerald Virtual Panel: Key Considerations for Gene Therapy Manufacturing and Platforms
GAINESVILLE, Fla., and CAMBRIDGE, Mass., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company focused on developing adeno-associated virus (AAV) based gene therapies for the treatment of rare inherited diseases, today announced that Sue Washer, President & Chief Executive Officer, and Dave Knop, PhD, Vice President, Process Development and Manufacturing, will participate in the Cantor Fitzgerald “Key Considerations for Gene Therapy Manufacturing and Platforms” virtual panel at 10:00 a.m. ET on Wednesday, October 28, 2020. The panel will focus on the critical components and capabilities to gene therapy manufacturing, including a discussion on AGTC’s proprietary manufacturing processes associated with AAV, and key company catalysts expected over the next 12 months. The call will be moderated by Kristen Kluska, Biotechnology Research Analyst of Cantor Fitzgerald.Presentation Information: Panel: Key Considerations for Gene Therapy Manufacturing and Platforms Date: Wednesday, October 28, 2020 Time: 10:00 a.m. – 11:30 a.m. ETTo register for the event, please click here.About AGTC AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. The Company’s most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa and achromatopsia (ACHM CNGB3 & ACHM CNGA3). Its pre-clinical programs build on the Company’s industry leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders.IR/PR CONTACTS:  David Carey (IR) or Glenn Silver (PR) Lazar FINN Partners T: (212) 867-1768 or (646) 871-8485 david.carey@finnpartners.com or glenn.silver@finnpartners.comCorporate Contact: Bill Sullivan Chief Financial Officer Applied Genetic Technologies Corporation T: (617) 843-5728 bsullivan@agtc.comStephen Potter Chief Business Officer Applied Genetic Technologies Corporation T: (617) 413-2754 spotter@agtc.com
GlobeNewswire · 10/21 12:00
AGTC Joins the My Retina Tracker® Program as a New Scientific Collaborator
GAINESVILLE, Fla., and CAMBRIDGE, Mass., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (AGTC), Blueprint Genetics, and Foundation Fighting Blindness, announce today that AGTC, a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene
GlobeNewswire · 10/07 12:00
Could The Applied Genetic Technologies Corporation (NASDAQ:AGTC) Ownership Structure Tell Us Something Useful?
The big shareholder groups in Applied Genetic Technologies Corporation (NASDAQ:AGTC) have power over the company...
Simply Wall St. · 09/12 14:20
Mid-Afternoon Market Update: Nasdaq Surges 300 Points; Slack Shares Plunge
Toward the end of trading Wednesday, the Dow traded up 2.32% to 28140.09 while the NASDAQ rose 2.87% to 11,159.42. The S&P also rose, gaining 2.44% to 3,413.24.
Benzinga · 09/09 18:30
Mid-Day Market Update: Dow Jumps Over 500 Points; Trillium Therapeutics Shares Spike Higher
Midway through trading Wednesday, the Dow traded up 1.90% to 28,024.77 while the NASDAQ rose 2.69% to 11,139.51. The S&P also rose, gaining 2.18% to 3,404.35.
Benzinga · 09/09 16:04
Intra-Cellular Therapies, Trillium Therapeutics leads gainers, Co-Diagnostics, Applied Genetic Technologies among losers
Gainers: Intra-Cellular Therapies (ITCI) +65%, Trillium Therapeutics (TRIL) +36%, Amryt Pharma (AMYT) +25%, BeyondSpring (BYSI) +18%, XTL Biopharmaceuticals (XTLB) +17%.Losers: Co-Diagnostics (CODX) -17%, Applied Genetic Technologies (AGTC) -16%, SCWorx (WORX) -10%, Innate Pharma (IPHA) -7%, PolarityTE (PTE) -5%.
Seekingalpha · 09/09 15:07
AGTC Provides Trial Design Update for its Phase 2/3 XLRP Clinical Trial, New Data on XLRP Higher Dose Group and Financial Results for the Fourth Quarter and Year Ended June 30, 2020
\- Planned Phase 2/3 trial expected to include approximately 60 patients and a responder analysis based on at least 7 decibel improvement in visual sensitivity in at least 5 loci across two active dose groups and one control group -\- Data from Group 5 supports use of higher dose level in Phase
GlobeNewswire · 09/09 12:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AGTC. Analyze the recent business situations of AGTC through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AGTC stock price target is 15.56 with a high estimate of 26.00 and a low estimate of 7.50.
EPS
Institutional Holdings
Institutions: 94
Institutional Holdings: 17.39M
% Owned: 67.23%
Shares Outstanding: 25.86M
TypeInstitutionsShares
Increased
22
2.24M
New
34
-126.80K
Decreased
10
757.42K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.34%
Pharmaceuticals & Medical Research
+1.30%
Key Executives
Chairman/Independent Director
Scott Koenig
President/Chief Executive Officer/Director
Susan Washer
Chief Financial Officer
William Sullivan
Executive Vice President
Matthew Feinsod
Chief Scientific Officer
Mark Shearman
Vice President
Stephen Potter
Independent Director
William Aliski
Independent Director
Edward Hurwitz
Independent Director
Ivana Magovcevic-Liebisch
Independent Director
James Rosen
Independent Director
Anne VanLent
Director
Ivana Magovcevic
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About AGTC
Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP). As of March 31, 2016, the Company was engaged in developing three discovery programs, targeting three indications based on its adeno-associated virus vector technologies. XLRS is an inherited retinal degenerative disease caused by mutations in the retinoschisis1 (RS1) gene. Achromatopsia is an inherited condition that is associated with visual acuity loss, extreme light sensitivity resulting in daytime blindness, and reduced or complete loss of color discrimination, achromatopsia is caused by mutations in any of several genes. The Company is also developing Alpha-1 Antitrypsin Deficiency (Alpha 1).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Applied Genetic Technologies Corp stock information, including NASDAQ:AGTC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGTC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AGTC stock methods without spending real money on the virtual paper trading platform.